-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 15, Zhejiang Medicine announced that it had recently received a "Drug Supplementary Application Approval Notice" of 0.
5g (500,000 units) of vancomycin hydrochloride for injection approved and issued by the National Medical Products Administration, and approved the drug to pass the quality of generic drugs.
And evaluation of consistency of efficacy
.
Vancomycin is a narrow-spectrum glycopeptide antibiotic produced by a strain of Streptomyces orientalis
.
Mainly effective against gram-positive bacteria, suitable for infections caused by methicillin-resistant Staphylococcus aureus and other bacteria: sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical trauma, etc.
Up to now, Zhejiang Medicine has invested about 6 million yuan in research and development expenses for the evaluation of the consistency of vancomycin hydrochloride for injection
.
The company's 2020 sales revenue of vancomycin hydrochloride for injection is 193,354,400 yuan